These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 26845121)

  • 21. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Levacq D; D'Haene N; de Wind R; Remmelink M; Berghmans T
    Lung Cancer; 2016 Dec; 102():38-41. PubMed ID: 27987586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
    Shea M; Huberman MS; Costa DB
    J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
    [No Abstract]   [Full Text] [Related]  

  • 23. Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy.
    Gu FF; Zhang Y; Liu YY; Hong XH; Liang JY; Tong F; Yang JS; Liu L
    J Hematol Oncol; 2016 Aug; 9(1):66. PubMed ID: 27496196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].
    Caliez J; Monnet I; Pujals A; Rousseau-Bussac G; Jabot L; Boudjemaa A; Leroy K; Chouaid C
    Rev Mal Respir; 2017 May; 34(5):576-580. PubMed ID: 27646667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
    Wang CG; Zeng DX; Huang JA; Jiang JH
    Medicine (Baltimore); 2018 Jan; 97(1):e9021. PubMed ID: 29505507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
    Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical response to crizotinib retreatment after acquisition of drug resistance.
    Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
    J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
    [No Abstract]   [Full Text] [Related]  

  • 30. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.
    Scarpino S; Rampioni Vinciguerra GL; Di Napoli A; Fochetti F; Uccini S; Iacono D; Marchetti P; Ruco L
    Lung Cancer; 2016 Jul; 97():95-8. PubMed ID: 27237034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
    Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
    Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
    Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
    J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.
    Ignatius Ou SH; Azada M; Hsiang DJ; Herman JM; Kain TS; Siwak-Tapp C; Casey C; He J; Ali SM; Klempner SJ; Miller VA
    J Thorac Oncol; 2014 Apr; 9(4):549-53. PubMed ID: 24736079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.
    Bahcall M; Sim T; Paweletz CP; Patel JD; Alden RS; Kuang Y; Sacher AG; Kim ND; Lydon CA; Awad MM; Jaklitsch MT; Sholl LM; Jänne PA; Oxnard GR
    Cancer Discov; 2016 Dec; 6(12):1334-1341. PubMed ID: 27694386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.